v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information

7. Segment Information

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is the Chief Executive Officer (CEO). The Company has determined it operates in a single operating segment and has one reportable segment. The segment consists of the development of clinical and preclinical product candidates for the discovery and development of innovative engineered T cell therapies and related administrative activities. The CODM assesses performance and allocates resources based on the Company’s consolidated statement of operations, which is reported on the income statement as consolidated net loss and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant. Further, the CODM reviews the segment’s assets based on the consolidated balance sheet to assess liquidity and funding capacity. The majority of the Company's assets are located in the United States.

The Company’s CODM views specific categories within expenses as significant given the direct correlation between cash burn and profitability as a pre-revenue company. Significant segment expenses, as provided to the CODM, are presented below. For additional information on the year over year change of segment expenses refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

(in thousands)

 

 

(in thousands)

 

Research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Manufacturing of preclinical and clinical supplies

 

$

13,855

 

 

$

11,610

 

 

$

24,647

 

 

$

16,642

 

Personnel

 

 

12,809

 

 

 

12,001

 

 

 

25,199

 

 

 

23,366

 

Clinical trials

 

 

11,430

 

 

 

9,070

 

 

 

22,434

 

 

 

17,581

 

License of intellectual property

 

 

3,000

 

 

 

—

 

 

 

3,000

 

 

 

—

 

Development services

 

 

2,178

 

 

 

4,197

 

 

 

4,534

 

 

 

7,765

 

Other research and development costs (1)

 

 

1,158

 

 

 

760

 

 

 

1,969

 

 

 

1,302

 

General and administration expenses

 

 

7,591

 

 

 

8,268

 

 

 

14,534

 

 

 

16,386

 

Interest income

 

 

(1,604

)

 

 

(1,410

)

 

 

(2,680

)

 

 

(2,897

)

Interest expense

 

 

517

 

 

 

571

 

 

 

1,153

 

 

 

865

 

Other (income) expense, net

 

 

84

 

 

 

61

 

 

 

(257

)

 

 

61

 

Net loss

 

$

51,018

 

 

$

45,128

 

 

$

94,533

 

 

$

81,071

 

(1) Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.